Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Apr 12, 2024

Keywords

ClinConnect Summary

The CompEER study is looking to compare two different methods of treating patients with acute kidney injury in the intensive care unit (ICU) who need kidney support. The two methods, called continuous venovenous hemodialysis (CVVHD) and continuous venovenous hemodiafiltration (CVVHDF), are both used to help remove waste products from the blood. The goal of this study is to find out which method is more effective at reducing a waste product called urea, which builds up when the kidneys aren’t working well. This research is important because it could improve how we manage patients in critical conditions.

To be eligible for this study, participants must be adults admitted to the ICU and require kidney support due to severe kidney injury. They should meet certain health criteria, such as having a high level of urea in their blood or a specific blood acidity level. However, individuals with end-stage kidney disease, certain medical conditions, or those who are pregnant or breastfeeding are not eligible. If someone participates in this study, they can expect to receive one of the two treatment methods and contribute to important research that could help improve care for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Adult patients hospitalized in ICU
• • Undergo RRT session because of AKI stage 3
• • At least one among criteria: pH \< 7,20 / Blood urea \> 30mM / Fluid overload uncontrolled by diuretics.
• • Patient having given free and informed consent, and having signed the consent form or patient included in an emergency situation
• • Patient affiliated with Social Security.
• Exclusion criteria:
• • End-stage chronic kidney disease on dialysis
• • Intoxication with a dialyzable toxin (lithium
• • Criteria for emergency dialysis initiation: hyperkaliemia \>6,5mM with electrocardiographic signs
• • Medical contraindication to regional citrate: severe liver failure
• • Medical contraindication to anticoagulation or heparin anticoagulation: heparin induced thrombopenia or uncontrolled bleeding
• • Pregnant women, parturient or breast-feeding patient